Results 11 to 20 of about 231,116 (154)

Recent Advances and Hot Spots of Neoadjuvant Immunotherapy Combined with Chemotherapy for Esophageal Carcinoma [PDF]

Zhongliu Fangzhi Yanjiu
Surgery-based multidisciplinary comprehensive treatment is the preferred treatment strategy for local advanced esophageal cancer. Neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy have been recommended by the Chinese Society of Clinical Oncology
Huilai LYU, Chunyue GAI, Mingbo WANG, Zhenhua LI, Jiachen LI, Shi XU, Weilu DING, Yu LIU, Ziqiang TIAN   +8 more
doaj   +2 more sources

Neoadjuvant SBRT combined with immunotherapy in NSCLC: from mechanisms to therapy [PDF]

Frontiers in Immunology, 2023
The utilisation of neoadjuvant immunotherapy has demonstrated promising preliminary clinical outcomes for early-stage resectable non-small-cell lung cancer (NSCLC).
Yanhong Shi, Xiaoyan Ma, Dan He, Bingwei Dong, Tianyun Qiao   +4 more
doaj   +2 more sources

Neoadjuvant immunotherapy for resectable esophageal cancer: A protocol of meta-analysis.

PLoS ONE, 2021
BackgroundEsophageal cancer is a highly malignant cancer with a very poor prognosis. For resectable esophageal cancer, neoadjuvant treatment could improve the prognosis of esophageal cancer.
Guocan Yu, Wenfeng Yu, Xudong Xu, Bo Ye, Liwei Yao   +4 more
doaj   +2 more sources

Rationalizing the pathway to personalized neoadjuvant immunotherapy: the Lombard Street Approach [PDF]

Journal for ImmunoTherapy of Cancer, 2020
Neoadjuvant chemo(radio)therapy is part of the established standard of care in cancer treatment; neoadjuvant application of immunotherapy, however, is only performed within recent trials.
Christian U Blank, Judith M Versluis, Daniela S Thommen   +2 more
doaj   +2 more sources

Neoadjuvant immunotherapy facilitates resection of surgically-challenging lung squamous cell cancer. [PDF]

, 2021
Background Locally-advanced lung squamous cell carcinoma represents a special subset that is challenging to resect completely with surgery alone. Immunotherapy has achieved great success in treating late-stage lung cancer. However, whether neoadjuvant
Xu, Ke, Ma, Wenyan, Schmid, Ralph A., Sun, Beibei, Yang, Haitang, Yao, Feng, Wang, Zhexin, Al-Hurani, Mohammad Faisal, Fan, Liwen   +8 more
core   +2 more sources

The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis

BMC Cancer, 2020
Background Immunotherapy has become an essential part of cancer treatment after showing great efficacy in various malignancies. However, its effectiveness in pancreatic ductal adenocarcinoma (PDAC), especially in resectable pancreatic cancer, has not ...
Saber Amin, Michael Baine, Jane Meza, Chi Lin   +3 more
doaj   +1 more source

Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis

Frontiers in Immunology, 2023
BackgroundThe neoadjuvant use of immune checkpoint inhibitor combined with chemotherapy (nICT) or chemoradiotherapy (nICRT) in locally advanced esophageal cancer (EC) is currently an area of active ongoing research.
Hao Qin, Futao Liu, Yaozhong Zhang, Yuxiang Liang, Yuan Mi, Fan Yu, Haidi Xu, Kuankuan Li, Chenxi Lin, Lei Li, Ziqiang Tian, Lei Wang   +11 more
doaj   +1 more source

Application of Neoadjuvant Immuno-chemotherapy in NSCLC

Chinese Journal of Lung Cancer, 2021
Even patients after standard surgery and adjuvant chemotherapy still have a high risk of recurrence and metastasis. With the success of immunotherapy in advanced non-small cell lung cancer (NSCLC), the application of immunotherapy in locally advanced ...
Si CHEN, Zerui ZHAO, Hao LONG
doaj   +1 more source

Current Status of Immunotherapy in Neoadjuvant Therapy for Gastric Cancer

Zhongliu Fangzhi Yanjiu, 2022
The majority of diagnosed cases of gastric cancer are in the middle and late stages, while less than 10% of patients are diagnosed in the early stages in China.
CHEN Bojin, HU Xingyi, ZHAO Jingwen, ZHENG Aihong   +3 more
doaj   +1 more source

Short-term outcome of neoadjuvant immunotherapy and chemotherapy in non–small cell lung cancer: A systematic review and meta-analysisCentral MessagePerspective

JTCVS Open, 2021
Background: Previously reported results have shown promising efficacy of neoadjuvant immunotherapy for resectable non–small cell lung cancer (NSCLC). However, no randomized control trials comparing neoadjuvant immunotherapy with chemotherapy have yet ...
Chao Zhang, MD, Hui-Zhao Hong, MD, Yi-Long Wu, MD, Wen-Zhao Zhong, MD, PhD   +3 more
doaj   +1 more source